MapLight Therapeutics, Inc. (MPLT)
MapLight Therapeutics develops treatments for central nervous system disorders, with candidates in clinical trials for schizophrenia and autism. It last closed at $6.57 on Nov 17, down 4.78% on the day. MPLT last reported earnings on Fri, Sep 18, 2026. The average 12-month price target from 2 analysts is $32.00 (+387.1% from the last close), with a high of $43.00 and a low of $21.00.
Key Stats
Last 12 monthsNot reported for this period.
From MPLT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on MPLT in the past 90 days. The average target is $32.00, with a high of $43.00 and a low of $21.00, compared with the last close of $6.57.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 17 | Canaccord Genuity | Target lowered | Buy | $24 → $21 |
| Aug 31 | Needham | Target lowered | Buy | $45 → $43 |
| Aug 10 | UBS | Downgrade | Hold | $52 → $13 |
| Jul 28 | Canaccord Genuity | Target lowered | Buy | $43 → $24 |
| Jul 28 | Morgan Stanley | Downgrade | Hold | $21 |
Technical Analysis
The stock is 12% below its 20 day and 38% below its 50 day average. It is 202% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 35), near oversold. The nearest support is the Pivot S1 at $6.36, and the nearest resistance the Pivot at $6.63.
| RSI (14) | 34.57 | Weak, oversold below 30 | Neutral |
| MACD | -0.62 | Above its signal line | Bullish |
| Stochastic | 39.2 | Middle of its range | Neutral |
| ADX (14) | 45.7 | Strong downtrend | |
| Williams %R | -76.1 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -106.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −3.5% | Change over 10 sessions | Bearish |
| ATR (14) | $0.60 | Typical daily range, 9.1% of price |
| RSI (14) | 29.69 | Oversold below 30 | Oversold |
| MACD | -4.38 | Below its signal line | Bearish |
| Stochastic | 10.5 | Near the bottom of its range | Oversold |
| ADX (14) | 37.6 | Trending down | |
| Williams %R | -93.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -71.9 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −49.5% | Change over 10 sessions | Bearish |
| ATR (14) | $2.83 | Typical daily range, 43.1% of price |
What happened before
See how MPLT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in MPLT in the last 90 days.
MPLT Institutional Ownership
Full report →- ●59 buying vs 54 selling
- ▲Held by funds +11.5 pts
- ▼Funds holding -9
- ▲Superinvestors: 3 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 98 | 107 | −8.4% |
| In funds' top 10 | 3 | 8 | −62.5% |
| Held by funds | 73.3% | 61.9% | +11.5 pts |
| New / increased | 20 / 39 | 37 / 21 | +1.7% |
| Reduced / sold out | 27 / 27 | 29 / 10 | +38.5% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MPLT is in one of them and how their past MPLT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MPLT in an article yet. Here's the latest on the wider market.
About MapLight Therapeutics
MapLight Therapeutics is a biopharmaceutical company based in Redwood City, California, that develops medicines for disorders of the central nervous system. Its main candidate, ML-007C-MA, is in clinical trials for schizophrenia and for psychosis linked to Alzheimer's disease. The company is also testing ML-004 for social communication difficulties in autism and has several preclinical programs. Its treatments are aimed at patients and the prescribers who care for them.
- Headquarters
- Redwood City, CA



